DWJ-1248(DWJ-1248) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

DWJ1248

靶点-

作用方式-

作用机制-

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

新型冠状病毒感染

原研机构

Daewoong Pharmaceutical Co., Ltd.

在研机构-

非在研机构

Daewoong Pharmaceutical Co., Ltd.

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 DWJ-1248 相关的临床试验

NCT04942054

/ Terminated临床1期

A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients

A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or with out ESR1 mutation.

开始日期2022-05-20

申办/合作机构

Sun Pharma Advanced Research Co. Ltd.

NCT04721535

/ Terminated临床3期

A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.

开始日期2021-06-07

申办/合作机构

Daewoong Pharmaceutical Co., Ltd.

NCT04782505

/ Completed临床1期

A Open-label, Single-dose, Phase 1 Study to Compare and Evaluate the Safety and Pharmacokinetics According to the Dose of Camostat Mesylate in Healthy Volunteers

Safety and pharmacokinetics evaluation study according to the dose of camostat mesylate in healthy volunteers

开始日期2021-03-12

申办/合作机构

Daewoong Pharmaceutical Co., Ltd.

100 项与 DWJ-1248 相关的临床结果

登录后查看更多信息

100 项与 DWJ-1248 相关的转化医学

登录后查看更多信息

100 项与 DWJ-1248 相关的专利（医药）

登录后查看更多信息

1

项与 DWJ-1248 相关的文献（医药）

2023-01-24·Antimicrobial agents and chemotherapy

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19

Article

作者: Han, Jumi ; Oh, Myoung-don ; Ra, Seung Won ; Kim, Yeonjae ; Kang, Beo Deul ; Lee, Ji Yeon ; Kang, Seung ji ; Choi, Jae-phil ; Shin, Yun Chul ; Choi, Jongwon ; Park, Hyun-jin ; Park, MiHee ; Lee, Boyoung ; Jung, Minji ; Kim, Sung-Han ; Han, Se Hee ; Kim, Junghee ; Yoon, Aeri ; Kim, Hyun ah ; Kim, YuKyung ; Koh, Jong Hoon ; Jeon, Seng-Ho ; Kim, Jin Yong ; Kim, Choon Kwan ; Kim, JooHyun ; Kim, Hyoung jun ; Kim, Yeon-Sook ; Peck, Kyong Ran ; Kim, Ji Won ; Heo, Jung Yeon ; Park, Chul Hee ; Lee, Chung Hoon ; Yu, Shi Nae ; Park, SuJung

Although several antiviral agents have become available for coronavirus disease 2019 (COVID-19) treatment, oral drugs are still limited. Camostat mesylate, an orally bioavailable serine protease inhibitor, has been used to treat chronic pancreatitis in South Korea, and it has an in vitro inhibitory potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

100 项与 DWJ-1248 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	韩国	Daewoong Pharmaceutical Co., Ltd.	2021-02-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04521296 (Pubmed)	临床2期	新型冠状病毒感染	432	Camostat Mesylate (DWJ1248)	襯壓壓憲蓋糧夢簾鹽膚(鹹憲醖憲壓憲願蓋鑰齋) = 糧蓋選淵夢選鬱窪衊顧範鬱簾選顧遞醖糧鹽鏇 (壓窪齋鹽淵齋醖顧構艱 ) 更多	不佳	2022-12-14
				Placebo	襯壓壓憲蓋糧夢簾鹽膚(鹹憲醖憲壓憲願蓋鑰齋) = 壓壓繭糧鏇糧顧鬱鏇繭範鬱簾選顧遞醖糧鹽鏇 (壓窪齋鹽淵齋醖顧構艱 ) 更多